A REVIEW: EFIKASI DAN KEAMANAN MOKSIFLOKSASIN DIBANDINGKAN LEVOFLOKSASIN SEBAGAI MONOTERAPI PADA PASIEN COMMUNITY-ACQUIRED PNEUMONIA RAWAT INAP
DOI:
https://doi.org/10.51574/illea.v2i3.6069Keywords:
pneumonia, moksifloksasin, levofloksasin, efikasiAbstract
Community-acquired pneumonia (CAP) remains a major cause of hospitalization and mortality worldwide. Respiratory fluoroquinolones such as moxifloxacin and levofloxacin are recommended as empirical therapy for hospitalized CAP patients without resistant pathogen risk factors.This review article aimed to compare the efficacy and safety of moxifloxacin and levofloxacin as monotherapy in hospitalized CAP patients. Literature search was conducted through PubMed, Scopus, and ScienceDirect databases for publications between 2016–2026. Clinical cure rate, minimum inhibitory concentration (MIC), epithelial lining fluid (ELF) penetration, pharmacokinetic/pharmacodynamic parameters, and adverse event profiles were analyzed. The findings indicate that moxifloxacin demonstrates higher clinical cure rates, lower MIC values against major respiratory pathogens, and greater ELF penetration compared to levofloxacin. Both agents show comparable safety profiles; however, moxifloxacin is more associated with QT interval prolongation, whereas levofloxacin presents higher risk of severe hypoglycemia in diabetic patients. Overall, moxifloxacin appears superior as empirical therapy for hospitalized CAP with appropriate patient selection.
References
Annisa, N., Barliana, M. I., Santoso, P., & Ruslami, R. (2022). Transporter and Metabolizer Gene Polymorphisms Affect Fluoroquinolone Pharmacokinetic Parameters. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.1063413
Barberán, J., De La Cuerda, A., González, M. I. T., Aparicio, A. L., Vinuesa, C. M., Sánchez, A. R., & Barberán, L. C. (2024). Safety of Fluoroquinolones. Revista Espanola de Quimioterapia, 37(2), 127–133. https://doi.org/10.37201/req/143.2023
Cilloniz, C., Dela Cruz, C. S., & Dy-Agra, G. (2024). World Pneumonia Day 2024: Fighting Pneumonia and Antimicrobial Resistance. American Journal of Respiratory and Critical Care Medicine, 210(11), 1283–1285. https://doi.org/10.1164/rccm.202408-1540ED
Dao, T. H., Echlin, H., McKnight, A., Marr, E. S., Junker, J., Jia, Q., Hayden, R., van Opijnen, T., Isberg, R. R., Cooper, V. S., & Rosch, J. W. (2024). Streptococcus pneumoniae favors Tolerance via Metabolic Adaptation Over Resistance to Circumvent Fluoroquinolones. American Society for Microbiology, 15(2). https://doi.org/10.1128/mbio.02828-23
Drwiega, E. N., & Rodvold, K. A. (2022). Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update. Clinical Pharmacokinetics, 61(1), 17–46. https://doi.org/10.1007-/s40262-021-01061-7
Du, X., Han, Y., Jian, Y., Chen, L., & Xuan, J. (2021a). Clinical Benefits and Cost-Effectiveness of Moxifloxacin as Initial Treatment for Community-Acquired Pneumonia: A Meta-Analysis and Economic Evaluation. Clinical Therapeutics, 43(11), 1894-1909.e1. https://doi.org/10.1016/-j.clinthera.2021.03.006
Du, X., Han, Y., Jian, Y., Chen, L., & Xuan, J. (2021b). Clinical Benefits and Cost-Effectiveness of Moxifloxacin as Initial Treatment for Community-Acquired Pneumonia: A Meta-Analysis and Economic Evaluation. Clinical Therapeutics, 43(11), 1894-1909.e1. https://doi.org/10.1016/-j.clinthera.2021.03.006
El-sagheir, A. M. K., Wenzel, M., & Yli-Kauhaluoma, J. (2025). Fluoroquinolones as Versatile Scaffolds: Potential for Targeting Classical and Novel Mechanisms to Combat Antibacterial Resistance. European Journal of Pharmaceutical Sciences, 214. https://doi.org/10.1016-/j.ejps.2025.107247
Finazzi, S., Luci, G., Olivieri, C., Langer, M., Mandelli, G., Corona, A., Viaggi, B., & Di Paolo, A. (2022). Tissue Penetration of Antimicrobials in Intensive Care Unit Patients: A Systematic Review—Part I. Antibiotics, 11(9). https://doi.org/10.3390/antibiotics11091164
GBD. (2025). Global Burden of Lower Respiratory Infections and Aetiologies, 1990–2023: A Systematic Analysis for the Global Burden of Disease Study 2023. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(25)00689-9
Geremia, N., Giovagnorio, F., Colpani, A., De Vito, A., Botan, A., Stroffolini, G., Toc, D. A., Zerbato, V., Principe, L., Madeddu, G., Luzzati, R., Parisi, S. G., & Di Bella, S. (2024). Fluoroquinolones and Biofilm: A Narrative Review. In Pharmaceuticals (Vol. 17, Number 12). Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/ph17121673
Guo, I. J., Maximos, M., & Gamble, J.-M. (2024). Examining Hypoglycemia Risk with Systemic Fluoroquinolone Use: A Systematic Review and Meta-Analysis. CMI Communications, 1(2), 105038. https://doi.org/10.1016/j.cmicom.2024.105038
Jonville-Béra, A. P., Largeau, B., di Meglio, F., & Pariente, A. (2025). The Safety Profile of Fluoroquinolones. Infectious Diseases Now, 55(4). https://doi.org/10.1016/j.idnow.2025.105064
Kato, H. (2024). Antibiotic Therapy for Bacterial Pneumonia. Journal of Pharmaceutical Health Care and Sciences, 10(1). https://doi.org/10.1186/s40780-024-00367-5
Li, S., Li, L., Wang, S., & Wu, H. (2025). Clinical Characteristics and Risk Factors of Hospital Mortality in Elderly Patients with Community-Acquired Pneumonia. Frontiers in Medicine, 12. https://doi.org/10.3389/fmed.2025.1512288
Liao, S. H., Hu, S. Y., How, C. K., Hsieh, V. C. R., Chan, C. M., Chiu, C. S., & Hsieh, M. S. (2022). Risk for Hypoglycemic Emergency with Levofloxacin Use, A Population-Based Propensity Score Matched Nested Case-Control Study. PLoS ONE, 17(4 April). https://doi.org/10.1371-/journal.pone.0266471
Metlay, J. P., Waterer, G. W., Long, A. C., Anzueto, A., Brozek, J., Crothers, K., Cooley, L. A., Dean, N. C., Fine, M. J., Flanders, S. A., Griffin, M. R., Metersky, M. L., Musher, D. M., Restrepo, M. I., & Whitney, C. G. (2019). Diagnosis and treatment of adults with community-acquired pneumonia. American Journal of Respiratory and Critical Care Medicine, 200(7), E45–E67. https://doi.org/10.1164/rccm.201908-1581ST
Muanda, F. T., Sood, M. M., Weir, M. A., Sontrop, J. M., Ahmadi, F., Yoo, E., Kim, R. B., Silverman, M. S., Knoll, G. A., & Garg, A. X. (2022). Association of Higher-Dose Fluoroquinolone Therapy With Serious Adverse Events in Older Adults With Advanced Chronic Kidney Disease. JAMA Network Open, 5(8), e2224892. https://doi.org/10.1001/jamanetworkopen.2022.24892
Rusu, A., Munteanu, A. C., Arbănași, E. M., & Uivarosi, V. (2023). Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile? Pharmaceutics, 15(3). https://doi.org/10.3390/pharmaceutics15030804
Sidamo, T., Rao, P. S., Aklillu, E., Shibeshi, W., Park, Y., Cho, Y. S., Shin, J. G., Heysell, S. K., Mpagama, S. G., & Engidawork, E. (2022). Population Pharmacokinetics of Levofloxacin and Moxifloxacin, and the Probability of Target Attainment in Ethiopian Patients with Multidrug-Resistant Tuberculosis. Infection and Drug Resistance, 15, 6839–6852. https://doi.org/10.2147/IDR.S389442
Täubel, J., Prasad, K., Rosano, G., Ferber, G., Wibberley, H., Cole, S. T., Van Langenhoven, L., Fernandes, S., Djumanov, D., & Sugiyama, A. (2020). Effects of the Fluoroquinolones Moxifloxacin and Levofloxacin on the QT Subintervals: Sex Differences in Ventricular Repolarization. Journal of Clinical Pharmacology, 60(3), 400–408. https://doi.org/10.1002/jcph.1534
Teng, G. L., Chi, J. Y., Zhang, H. M., Li, X. P., & Jin, F. (2023). Oral vs. Parenteral Antibiotic Therapy in Adult Patients with Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Global Antimicrobial Resistance, 32, 88–97. https://doi.org/10.1016/j.jgar.2022.12.010
Tse, J., Near, A. M., Cheng, M., Karichu, J., Lee, B., & Chang, S. N. (2022). Outpatient Antibiotic and Antiviral Utilization Patterns in Patients Tested for Respiratory Pathogens in the United States: A Real-World Database Study. Antibiotics, 11(8). https://doi.org/10.3390/antibiotics11081058
Wang, M., Zhang, J., Wang, X., Wang, Q., Wang, L., Zhuang, H., & Liu, A. (2025). Comparison of initial empirical antibiotic regimens in severe community-acquired pneumonia: a network meta-analysis. BMC Pulmonary Medicine, 25(1). https://doi.org/10.1186/s12890-025-03695-w
Xu, L. Y., Wang, C. C., Peng, X. X., Jiao, Y., Zhao, C. Z., Zhang, L., & Ma, L. (2022). Empirical Antibiotic Treatment Strategies for Community-Acquired Pneumonia: A Network Meta-Analysis. Journal of Global Antimicrobial Resistance, 30, 1–9. https://doi.org/10.1016/j.jgar.2022.05.009
